

Effective as of **10/21/2024**

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Information regarding Current Procedural Terminology (CPT)

| Test Number | Mnemonic | Test Name | New Test | Test Name Change | Specimen Requirements | Methodology | Performed/Reported | Note | Interpretive Data | Reference Interval | Component Charting Name | Component Change | Reflex Pattern | Result Type | Ask at Order Prompt | Numeric Map | Unit of Measure | CPT Code | Pricing Change | Inactivation w/ Replacement | Inactivation w/o Replacement |
|----------------|-------------------|---|----------|------------------|-----------------------|-------------|--------------------|------|-------------------|---------------------------|--------------------------------|-------------------------|----------------|-------------|---------------------|-------------|-----------------|----------|----------------|-----------------------------|------------------------------|
| 0020407 | LACTOL | Lactose Tolerance (Inactive as of 10/21/24) | | | | | | | | | | | | | | | | | | | x |
| 0060113 | MC LEGION | Legionella Species, Culture | | | x | x | | x | | | | | | | | | | | | | |
| 0082024 | FFN | Fetal Fibronectin (Inactive as of 10/21/24) | | | | | | | | | | | | | | | | | | | x |
| 0090001 | Acetaminop hen | Acetaminophen(Inactive as of 10/21/24) | | | | | | | | | | | | | | | | | | | x |
| 0090057 | GABAP | Gabapentin (Change effective as of 10/21/2024: Refer to 3017893 in the October Hotline) | | | | | | | | | | | | | | | | | | x | |
| 0090090 | DIL | Phenytoin(Change effective as of 10/21/24: Refer to 0090141 in the October Hotline) | | | | | | | | | | | | | | | | | | x | |
| 0090251 | Salicylate | Salicylate Assay (Inactive as of 10/21/24) | | | | | | | | | | | | | | | | | | | x |
| 0090260 | TEG | Carbamazepine, Total (Change effective as of 10/21/24: Refer to 2011763 in the October Hotline) | | | | | | | | | | | | | | | | | | x | |
| 0090290 | VPA | Valproic Acid(Change effective as of 10/21/24: Refer to 0099310 in the October Hotline) | | | | | | | | | | | | | | | | | | x | |



Effective as of **10/21/2024**

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Information regarding Current Procedural Terminology (CPT)

| Test Number | Mnemonic | Test Name | New Test | Test Name Change | Specimen Requirements | Methodology | Performed/Reported | Note | Interpretive Data | Reference Interval | Component Charting Name | Component Change | Reflex Pattern | Result Type | Ask at Order Prompt | Numeric Map | Unit of Measure | CPT Code | Pricing Change | Inactivation w/ Replacement | Inactivation w/o Replacement |
|----------------|---------------|---|----------|------------------|-----------------------|-------------|--------------------|------|-------------------|--------------------|--------------------------------|-------------------------|----------------|-------------|---------------------|-------------|-----------------|----------|-----------------------|-----------------------------|------------------------------|
| 0095229 | CYSTAT C | Cystatin C, Serum with Reflex to Estimated Glomerular Filtration Rate (eGFR) (Change effective as of 10/21/24: Refer to 3018316 in the October Hotline.) | | | | | | | | | | | | | | | | | | x | |
| 0098834 | OXCARB | Oxcarbazepine or Eslicarbazepine Metabolite (MHD) (Change effective as of 10/21/2024: Refer to 3017889 in the October Hotline) | | | | | | | | | | | | | | | | | | x | |
| 2000133 | GH REQUEST | Cytology, SurePath Liquid-Based Pap Test and Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, SurePath. (for routine co-testing in women over 30) (Change effective as of 10/21/2024: Refer to 2000136) | | | | | | | | | | | | | | | | | | x | |
| 2000134 | GA REQUEST | Cytology, SurePath Liquid-Based Pap Test (Change effective as of 10/21/2024: Refer to 2000137) | | | | | | | | | | | | | | | | | | x | |



Effective as of **10/21/2024**

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid Information regarding Current Procedural Terminology (CPT)

| Test Number | Mnemonic | Test Name | New Test | Test Name Change | Specimen Requirements | Methodology | Performed/Reported | Note | Interpretive Data | Reference Interval | Component Charting Name | Component Change | Reflex Pattern | Result Type | Ask at Order Prompt | Numeric Map | Unit of Measure | CPT Code | Pricing Change | Inactivation w/ Replacement | Inactivation w/o Replacement |
|----------------|---------------|---|----------|------------------|-----------------------|-------------|--------------------|------|-------------------|--------------------|--------------------------------|-------------------------|----------------|-------------|---------------------|-------------|-----------------|----------|----------------|-----------------------------|------------------------------|
| 2000135 | GR REQUEST | Cytology, SurePath Liquid-Based Pap Test with Reflex to Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, SurePath (Change effective as of 10/21/2024: Refer to 2000138) | | | | | | | | | | | | | | | | | | x | |
| 2003182 | LACOSA SP | Lacosamide, Serum or Plasma (Change effective as of 10/21/2024: Refer to 3017887 in the October Hotline) | | | | | | | | | | | | | | | | | | x | |
| 2005415 | UIAT | Urticaria-Inducing Activity with Thyroid Antibodies and Stimulating Hormone | | | x | | | | | | | | | | | | | | | | |
| 2005966 | MEL BL SS | Special Stain, Melanin Bleach | | | x | | | | | | | | | | | | | | | | |
| 2007515 | TADQNT U | Tricyclic Antidepressants, Quantitative, Urine | | | | | x | | | | | x | | | | | | | | | |
| 2012669 | HIV AB DIF | Human Immunodeficiency Virus Types 1 and 2 (HIV-1/2) Antibody Differentiation, Supplemental, with Reflex to HIV-1 Quantitative NAAT, Plasma | | x | x | | | x | | | | | x | | | | | x | | | |



Effective as of **10/21/2024**

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid Information regarding Current Procedural Terminology (CPT)

| Test Number | Mnemonic | Test Name | New Test | Test Name Change | Specimen Requirements | Methodology | Performed/Reported | Note | Interpretive Data | Reference Interval | Component Charting Name | Component Change | Reflex Pattern | Result Type | Ask at Order Prompt | Numeric Map | Unit of Measure | CPT Code | Pricing Change | Inactivation w/ Replacement | Inactivation w/o Replacement |
|----------------|----------------|--|----------|------------------|------------------------------|-------------|--------------------|------|-------------------|--------------------|--------------------------------|-------------------------|----------------|-------------|---------------------|-------------|-----------------|----------|-----------------------|-----------------------------|------------------------------|
| 2012674 | HIV PANEL | Human Immunodeficiency Virus (HIV) Combo Antigen/Antibody (HIV- 1/O/2) by CIA, Reflexive Panel | | | x | | | x | | | | | | | | | | x | | | |
| 2013333 | HIVAGABGE | Human Immunodeficiency Virus (HIV) Combo Antigen/Antibody (HIV- 1/0/2) by CIA with Reflex to HIV-1/HIV-2 Antibody Differentiation, Supplemental | | | x | | | x | | | | | | | | | | | | | |
| 3000496 | PANFUNGSE Q | PanFungal Identification by Sequencing | | | x | | | | | | | | | | | | | | | | |
| 3000867 | HIV QNT | Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, Plasma | | | x | x | | x | x | | | | | | | | | | | | |
| 3000870 | HIV QT GR | Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT with Reflex to HIV- 1 Drug Resistance by Next Generation Sequencing | | | x | x | | | | x | | | | | | | | | | | |
| 3000872 | HIVCSF QNT | Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, CSF | | | x | x | | x | x | | | | | | | | | | | | |



Effective as of 10/21/2024

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid

Information regarding Current Procedural Terminology (CPT)

| Test Number | Mnemonic | Test Name | New Test | Test Name Change | Specimen Requirements | Methodology | Performed/Reported | Note | Interpretive Data | Reference Interval | Component Charting Name | Component Change | Reflex Pattern | Result Type | Ask at Order Prompt | Numeric Map | Unit of Measure | CPT Code | Pricing Change | Inactivation w/ Replacement | Inactivation w/o Replacement |
|----------------|---------------|---|----------|------------------|-----------------------|-------------|--------------------|------|-------------------|---------------------------|--------------------------------|-------------------------|----------------|-------------|---------------------|-------------|-----------------|----------|-----------------------|-----------------------------|------------------------------|
| 3003760 | HIV1 QUAL | Human Immunodeficiency Virus 1 (HIV-1) by Qualitative NAAT (Change effective as of 10/21/24; Refer to 3017779 in the October Hotline) | | | | | | | | | | | | | | | | | | x | |
| 3005478 | GFR EST | Creatinine With eGFR | | x | | | | | | | х | | | | | | | | | | |
| 3005694 | ARRAY FSV | Cytogenomic SNP Microarray, Family- Specific Variant | x | | | | | | | | | | | | | | | | | | |
| 3017653 | ADMRKS CSF | Alzheimer's Disease Markers, CSF | | | | | | | | | | | | | | | | | x | | |
| 3017779 | HIV1,2QUAL | Human Immunodeficiency Virus 1 and 2 (HIV-1/HIV-2) by Qualitative NAAT | x | | | | | | | | | | | | | | | | | | |
| 3017828 | SO MSI IHC | Mismatch Repair Panel by Immunohistochemistry | x | | | | | | | | | | | | | | | | | | |
| 3017887 | LACOSA-S | Lacosamide, Serum | х | | | | | | | | | | | | | | | | | | |
| 3017889 | OXCARBAZ | Oxcarbazepine Metabolite, Serum | x | | | | | | | | | | | | | | | | | | |
| 3017890 | 14-3-3 ETA | 14-3-3 eta Protein by ELISA, Serum | x | | | | | | | | | | | | | | | | | | |
| 3017891 | RAPANEL | Early and Established Rheumatoid Arthritis (RA) Panel | x | | | | | | | | | | | | | | | | | | |
| 3017893 | GABAP-SP | Gabapentin, Serum or Plasma | x | | | | | | | | | | | | | | | | | | |
| 3017902 | SC5B-9 | SC5b-9 | х | | | | | | | | | | | | | | | | | | |



Effective as of **10/21/2024**

Additional ordering and billing information

Information when ordering laboratory tests that are billed to Medicare/Medicaid Information regarding Current Procedural Terminology (CPT)

| Test Number | Mnemonic | Test Name | New Test | Test Name Change | Specimen Requirements | Methodology | Performed/Reported | Note | Interpretive Data | Reference Interval | Component Charting Name | Component Change | Reflex Pattern | Result Type | Ask at Order Prompt | Numeric Map | Unit of Measure | CPT Code | Pricing Change | Inactivation w/ Replacement | Inactivation w/o Replacement |
|----------------|-----------|---|----------|------------------|-----------------------|-------------|--------------------|------|-------------------|---------------------------|--------------------------------|-------------------------|----------------|-------------|---------------------|-------------|-----------------|----------|----------------|-----------------------------|------------------------------|
| 3018046 | CD38-IHC | CD38 by Immunohistochemistry | x | | | | | | | | | | | | | | | | | | |
| 3018056 | P120 IHC | p120 by Immunohistochemistry | x | | | | | | | | | | | | | | | | | | |
| 3018057 | MYOD1 IHC | MyoD1 by Immunohistochemistry | x | | | | | | | | | | | | | | | | | | |
| 3018058 | HLA A29 | HLA-A29 Genotyping, Birdshot Chorioretinopathy | x | | | | | | | | | | | | | | | | | | |
| 3018202 | VIP PLA | Vasoactive Intestinal Polypeptide (VIP), Plasma | x | | | | | | | | | | | | | | | | | | |
| 3018316 | GFR CYS | Cystatin and Creatinine With eGFR | x | | | | | | | | | | | | | | | | | | |
| 3018558 | JUG R 1 | Allergen, Food, Walnut Component rJug r 1, IgE | х | | | | | | | | | | | | | | | | | | |
| 3018559 | WALNUT R | Allergen, Food, Walnut (Juglans spp.) With Reflex to Components, IgE | x | | | | | | | | | | | | | | | | | | |
| 3018561 | ANA O 3 | Allergen, Food, Cashew Component rAna o 3, IgE | x | | | | | | | | | | | | | | | | | | |
| 3018562 | CASHEW R | Allergen, Food, Cashew With Reflex to Components, IgE | x | | | | | | | | | | | | | | | | | | |



TEST CHANGE

| Legionella Species, Culture 0060113, MC LEGION | |
|---|--|
| Specimen Requirements: | |
| Patient Preparation: | |
| Collect: | Respiratory specimens: Abscess material, aspirates, BAL, fluids, secretions, sputum, or tissue; OR pericardial fluid or blood in SPS Vacutainer(R) tube for microbiology (ARUP supply #24964). Available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at (800_)-522- 2787. |
| Specimen Preparation: | Fluid: Transfer to a sterile container. Place each specimen in an individually sealed bag. (Min. 0.5 mL) Tissue: Place on gauze moistened with sterile nonbacteriostatic saline to prevent drying and transport in sterile container. Blood: Transport blood in SPS tube. |
| Transport Temperature: | Refrigerated. For nonblood specimens: If delay in transport (greater than 48 hours), <u>freeze at -60C or lower and transport</u> on dry icefrozen. |
| Unacceptable Conditions: | Stool, urine, wounds, or other nonrespiratory sites. Dry specimens. Specimens in preservatives or viral transport medium (M4, UTM). |
| Remarks: | Specimen source preferred. |
| Stability: | Ambient: 2 hours; Refrigerated: 48 hours; Frozen: 1 week <u>Whole Blood: Ambient: 2 hours; Refrigerated: 48 hours; Frozen:</u> <u>Unacceptable</u> |
| Methodology: | Qualitative Culture/Identification |
| Performed: | Sun-Sat |
| Reported: | 1-8 days |
| Note: | Amplified DNA testing (PCR) is also available for respiratory specimens. Refer to Legionella Species by Qualitative PCR (<u>ARUP test code</u> 2010125). Legionella pneumophila DFA (ARUP test code 2004598) is also available. |
| CPT Codes: | 87081; Identification CPT codes may vary based on method |



New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Reference Interval:

Culture negative for *Legionella* species.



TEST CHANGE

Urticaria-Inducing Activity with Thyroid Antibodies and Stimulating Hormone

| 2005415, UIAT | |
|--------------------------|--|
| Specimen Requirements: | |
| Patient Preparation: | Patients taking calcineurin inhibitors should stop their medication 72 hours prior to draw. Patients on prednisone should be off their medication for 2 weeks prior to draw. |
| Collect: | Plain red. |
| Specimen Preparation: | Separate serum from cells ASAP or within 2 hours of collection. Transfer 1 mL serum <u>each</u> to <u>twoan</u> ARUP <u>standard transport</u> <u>tubesStandard Transport tube</u> and freeze immediately (Min: 0.5 mL <u>each</u>) AND transfer 1 mL serum to an ARUP Standard <u>Transport Tube. (Min: 0.5 mL</u>) |
| Transport Temperature: | First Specimen: CRITICAL FROZEN. Separate specimens must be submitted for this multiple test panel. <u>Second Specimen:</u> Refrigerated. |
| Unacceptable Conditions: | Specimens other than serum. Contaminated, grossly hemolyzed, or lipemic specimens. |
| Remarks: | |
| Stability: | First Specimen: After separation from cells: Ambient: 30 minutes; Refrigerated: Unacceptable; Frozen: 1 year (avoid repeated freeze/thaw cycles)—Second Specimen: After separation from cells: Ambient: 8 hours; Refrigerated: 1 Week; Frozen: 6 months |
| Methodology: | Semi-Quantitative Ex Vivo Challenge/Cell Culture/Quantitative Enzyme-Linked Immunosorbent Assay <u>(ELISA)/</u> /Quantitative Chemiluminescent Immunoassay <u>(CLIA)</u> |
| Performed: | Mon, Fri |
| Reported: | 11-14 days |
| Note: | 1) Chronic urticaria (CU) is a common and complex dermatological condition that is suspected when patients experience persistent hives for over 6 weeks. No published evidence of an exogenous allergen as the cause of this disorder exists. About 45 percent of cases have autoantibodies directed against either basophil or mast cell-associated IgE or the high <u>_</u> affinity IgE-Fc receptor (Fc epsilon R1 alpha) (Clin Exp Allergy |



2009; 39: 777-87). 2) The presence of histamine-releasing factors (including but not limited to IgE and Fc epsilon R1 alpha-specific autoantibodies) in the patient serum can be indirectly determined by evaluating basophil/mast cell activation status using histamine-release assays, autologous serum-skin test, and flow cytometric measurement of the basophil and mast cell-specific marker CD203c. Serum from CU patients can activate donor basophils, which induces histamine release and CD203c upregulation (J Allergy Clin Immunol 2006; 117: 1430-4).

| CPT Codes: | 86352; 86800; 84443; 86376 |
|--|---|
| New York DOH Approval Status: | This test is New York DOH approved. |
| Interpretive Data: | |
| Refer to report. Refer to report. | |
| This test was developed and its pe | rformance characteristics determined by ARUP Laboratories. It |
| has not been cleared or approved b | by the US Food and Drug Administration. This test was |
| performed in a CLIA certified laboration | atory and is intended for clinical purposes. |
| Reference Interval: | |

By report



TEST CHANGE

| Special Stain, Melanin Bleach 2005966, MEL BL SS | |
|---|---|
| Specimen Requirements: | |
| Patient Preparation: | |
| Collect: | Tissue or cells. |
| Specimen Preparation: | Formalin fix (10 percent neutral buffered formalin is preferred) and paraffin embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 2 unstained (3- to 5-micron thick sections), positively charged slides in a tissue transport kit (ARUP supply #47808). Available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at (800-)-522-2787. (Min: 2 slides1-slide). |
| Transport Temperature: | Room temperature or refrigerated. Ship in cooled container during summer months. |
| Unacceptable Conditions: | Specimens submitted with <u>nonrepresentativenon-</u> representative tissue type. Depleted specimens. |
| Remarks: | HISTOLOGY SPECIAL STAINS SUBMISSION DETAILS: Submit electronic request. If you do not have electronic ordering capability, use an ARUP Anatomic Pathology Form (#32960) with an ARUP client number. For additional technical details, contact ARUP Client Services at (800-)-522-2787. |
| Stability: | Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable |
| Methodology: | Special Stain |
| Performed: | Mon-Fri |
| Reported: | 1-5 days |
| Note: | All stains will be handled as Stain and Return unless a consultation is requested. To request a consultation, submit the pathology report, all associated case materials (clinical history, blocks, slides, etc.), and the Anatomic Pathology Requisition Form (#32960). |
| CPT Codes: | 88313 |



New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Reference Interval:

| Test | Components | Reference Interval |
|--------|------------|--------------------|
| Number | | |



TEST CHANGE

| 2007515, TADQNT U | |
|---|---|
| Specimen Requirements: | |
| Patient Preparation: | |
| Collect: Random urine. | |
| Specimen Preparation: Transfer 2 mL urine to ARUP standard transport tube. (Min: 0. mL) | 7 |
| Transport Temperature: Refrigerated. | |
| Unacceptable Conditions: | |
| Remarks: | |
| Stability: Ambient: 1 week; Refrigerated: 11 days; Frozen: 2 weeks | |
| Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry | |
| Performed: Sun Tue, Thu, Sat | |
| Reported: <u>2-81-7</u> days | |
| Note: This test is used to quantitate the following tricyclic antidepressants: amitriptyline, clomipramine, desipramine, doxepin, imipramine, norclomipramine, nordoxepin, nortriptyline, and protriptyline. | |
| CPT Codes: 80337 (Alt code: G0480) | |
| New York DOH Approval Status: This test is New York DOH approved. | |
| Interpretive Data: | |
| Urine concentrations of tricyclic antidepressants do not correlate with signs or symptoms of therapy or toxicity. | |
| Therapeutic ranges are not established. | |
| 100 ng/mL limit of quantification: Amitriptyline, nortriptyline, imipramine, desipramine, doxepin, nordoxepin, protriptyline | |
| 200 ng/mL limit of quantification: Clomipramine, norclomipramine | |



HOTLINE NOTE: There is a component change associated with this test. One or more components have been added or removed. Refer to the Hotline Test Mix for interface build information.



TEST CHANGE

Human Immunodeficiency Virus Types 1 and 2 (HIV-1/2) Antibody Differentiation, Supplemental, with Reflex to HIV-1 Quantitative NAAT, Plasma

2012669, HIV AB DIF

Specimen Requirements:

| Patient Preparation: | |
|--------------------------|--|
| Collect: | <u>Serum separator tube (SST), lavender</u> Lavender (EDTA), or pink (K2EDTA). |
| Specimen Preparation: | Separate from cells within 24 hours of collection. Transfer 3 mL serum or plasma into an ARUP standard transport tube dedicated only for <u>the HIV AB DIF assaytesting</u> . (Min: 1 <u>.5</u> mL) Remove particulate material. |
| Transport Temperature: | Frozen. |
| Unacceptable Conditions: | Serum. Heparinized or citrated plasma specimens. Specimens submitted in plasma preparation tube. Specimens containing particulate material. Severely hemolyzed or heat-inactivated specimens. |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 24 hours (CRITICAL: SHIP FROZEN); Refrigerated: <u>5 days72 hours</u> ; Frozen: <u>6 weeks</u> 3 months (avoid repeated freeze/thaw cycles) |
| Methodology: | Qualitative Polymerase Chain Reaction (PCR)/Qualitative Immunoassay/Quantitative Transcription-Mediated Amplification (TMA) |
| Performed: | Varies |
| Reported: | 1-2 days |
| Note: | For use only when patient has a repeatedly reactive third- or fourth-generation HIV screen test result. This test discriminates between HIV-1 and HIV-2 antibodies. Results for each type are reported. This test is for use as the antibody differentiation test in the specific multitest algorithm. It is not to be ordered as a rapid screen test and cannot be used as a supplemental test if the initial screen test was a rapid test. If the HIV-1/ 2 antibody differentiation immunoassay is Negative or Indeterminate, then the Human Immunodeficiency Virus 1 and 2 (HIV-1/HIV-2) by Qualntitative NAAT, Plasma, will be added. Additional charges apply. Refer to Human |



Immunodeficiency Virus 1 and 2 (HIV-1/HIV-2) by Qualntitative NAAT, Plasma (ARUP test code <u>3017779</u>3000867) for additional information regarding Performed or Reported times, Interpretive Data, and Notes for the reflex test. The multitest algorithm is recommended by the Centers for Disease Control and Prevention (CDC) and the Clinical Laboratory Standards Institute (CLSI) for the diagnosis of HIV (refer to http://arupconsult.com/content/human-immunodeficiencyvirus).

CPT Codes:

86701; 86702; if reflexed, add 875356

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

This test should not be used for blood donor screening, associated reentry protocols, or for screening human cells, tissues, and cellular- and tissue-based products (HCT/P).

Reference Interval:

Effective November 12, 2018

| Test Number | Components | Reference Interval |
|-------------|---|-----------------------|
| | HIV-1 Antibody | Negative |
| | HIV-2 Antibody | Negative |
| 3000867 | Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, Plasma | Not detected |

HOTLINE NOTE: There is a reflexive pattern change associated with this test. One or more orderable or component has been added or removed to the reflexive pattern. Refer to the Hotline Test Mix for interface build information.



TEST CHANGE

| Human Immunodeficiency Viru Reflexive Panel | s (HIV) Combo Antigen/Antibody (HIV-1/0/2) by CIA, |
|--|---|
| 2012674, HIV PANEL | |
| Specimen Requirements: | |
| Patient Preparation: | |
| Collect: | <u>Serum separator tube (SST), lavenderLavender</u> (EDTA <u>).</u>) or pink (K2EDTA). |
| Specimen Preparation: | Separate from cells within 24 hours of collection. Transfer 3 mL serum or plasma into an ARUP standard transport tube. (Min: 2.3 mL) Remove particulate material. This test requires a dedicated transport tube submitted only for <u>the</u> HIV <u>PANEL</u> <u>assay</u> testing. |
| Transport Temperature: | Frozen. |
| Unacceptable Conditions: | Serum. Heparinized or citrated plasma specimens. Plasma preparation tube. Specimens containing particulate material. Severely hemolyzed or heat-inactivated specimens. |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 24 hours (CRITICAL: SHIP FROZEN); Refrigerated: <u>5 days72 hours</u> ; Frozen: <u>6 weeks3</u> months (avoid repeated freeze/thaw cycles) |
| Methodology: | Qualitative Chemiluminescent Immunoassay (CLIA)/Qualitative Immunoassay/ <u>Qualitative Polymerase Chain Reaction</u> (PCRQuantitative Transcription-Mediated Amplification (TMA) |
| Performed: | Sun-Sat |
| Reported: | 1-2 days |
| Note: | The fourth-generation screen test is for the simultaneous qualitative detection of human ilmmunodeficiency virus type 1 (HIV-1) p24 antigen and antibodies to HIV type 1 (HIV-1 groups M and O) and HIV type 2 (HIV-2). Results of the screen cannot be used to distinguish between the presence of HIV-1 p24 antigen, HIV-1 antibody (Ab), or HIV-2 Ab. If the HIV-1,2 combo antigen/Ab screen is repeatedly reactive, then the HIV- 1/2 Ab differentiation immunoassay will be performed. Additional charges apply. The HIV-1/2 Ab differentiation immunoassay confirms and discriminates between HIV-1 and HIV-2 Abs. Results for each type are reported. If the HIV-1/2 |



Ab differentiation immunoassay is Negative or Indeterminate, then the Human Immunodeficiency Virus 1 and 2 (HIV-1/HIV-2) by Qualntitative NAAT, Plasma will be added. Additional charges apply. This multitest algorithm is recommended by the Centers for Disease Control and Prevention (CDC) and was adopted by the Clinical Laboratory Standards Institute (CLSI) for the diagnosis of HIV (refer to http://arupconsult.com/content/human-immunodeficiencyvirus). Refer to the following tests for additional information regarding Performed or Reported times, Interpretive Data, and Notes for the reflex tests of this panel: Human Immunodeficiency Virus Types 1 and 2 (HIV-1/2) Antibody Differentiation, Supplemental with Reflex to HIV-1/HIV-2 Qualitative Quantitative NAAT, Plasma (ARUP test code 2012669); Human Immunodeficiency Virus 1 and 2 (HIV-1/HIV-2) by Qualntitative NAAT, Plasma (ARUP test code <u>3017779</u>3000867).

 CPT Codes:
 87389; if reflexed, add 86701 and 86702; if reflexed, add

 875356

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

This test should not be used for blood donor screening, associated reentry protocols, or for screening human cells, tissues, and cellular- and tissue-based products (HCT/P).

Reference Interval:

| Test Number | Components | Reference Interval |
|----------------|--------------------------------|--------------------|
| | HIV 1,2 Combo Antigen/Antibody | Negative |

Effective November 12, 2018



TEST CHANGE

Human Immunodeficiency Virus (HIV) Combo Antigen/Antibody (HIV-1/0/2) by CIA with Reflex to HIV-1/HIV-2 Antibody Differentiation, Supplemental

| 2013333, HIVAGABGE | |
|--------------------------|--|
| Specimen Requirements: | |
| Patient Preparation: | N/A |
| Collect: | Serum separator tube (SST). Also acceptable: Lavender (EDTA) or pink (K2EDTA). |
| Specimen Preparation: | Separate from cells ASAP or within 2 hours of collection. Transfer 1.5 mL serum <u>or plasma</u> into an ARUP standard transport tube. (Min: 0.75 mL) Remove particulate material. |
| Transport Temperature: | FrozenRefrigerated. |
| Unacceptable Conditions: | Specimens containing particulate material. Severely hemolyzed or heat-inactivated specimens. |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 24 hours; Refrigerated: 7 days; Frozen: 8 months (avoid repeated freeze/thaw cycles) |
| Methodology: | Qualitative Chemiluminescent Immunoassay (CLIA)/Qualitative Immunoassay |
| Performed: | Sun-Sat |
| Reported: | 1-2 days |
| Note: | The fourth-generation screen test is for the simultaneous qualitative detection of human immunodeficiency virus type 1 (HIV-1) p24 antigen and antibodies to HIV type 1 (HIV-1 groups M and O) and HIV type 2 (HIV-2). Results of the screen cannot be used to distinguish between the presence of HIV-1 p24 antigen, HIV-1 antibody, or HIV-2 antibody. The reflexed HIV-1/ HIV-2 antibody differentiation test discriminates between HIV-1 and HIV-2 antibodies. Results for each type are reported. If the HIV-1,2 combo antigen/antibody screen is repeatedly reactive, then the HIV-1/ HIV-2 antibody differentiation test will be performed. Additional charges apply. A recommendation to order further testing on a separate specimen for HIV-1/ <u>HIV-2</u> nucleic acid will be made for certain results. This multitest algorithm is recommended by the Centers for Disease Control and Prevention (CDC) and was adopted by the Clinical |



Laboratory Standards Institute (CLSI) for the diagnosis of HIV.

| CPT Codes: | 87389; if reflexed, add 86701; 86702 | |
|-------------------------------|--------------------------------------|--|
| New York DOH Approval Status: | This test is New York DOH approved. | |

Interpretive Data:

This test should not be used for blood donor screening, associated reentry protocols, or for screening human cell, tissues, and cellular- and tissue-based products (HCT/P).

Reference Interval:

| Test Number | Components | Reference Interval |
|----------------|--------------------------------|--------------------|
| | HIV 1,2 Combo Antigen/Antibody | Negative |

TEST CHANGE

| PanFungal Identification by Sequencing 3000496, PANFUNGSEQ | | |
|---|--|--|
| Specimen Requirements: | | |
| Patient Preparation: | | |
| Collect: | <u>Fresh tissue; formalin-fixed paraffin-embedded tissue (FFPE);</u> <u>CSF; pleural, abdominal, synovial, peritoneal, and vitreous fluid.</u> Tissue, CSF, body fluid | |
| Specimen Preparation: | Formalin-fixed paraffin-embedded tissue block (FFPE) *Scrolls minimum; three (10 microns). Transfer fresh tissue, CSF, tissue, ander body fluid specimen intote a sterile container and freeze immediately. *Fresh tissue minimum(Min: 25 mg. *-of fresh tissue or 0.5mL of CSF/Sterile body fluid minimum 0.5 mL.) Also acceptable: Formalin-fixed paraffin-embedded (FFPE) tissue. (Min: three 10 micron scrolls). | |
| Transport Temperature: | Fresh Tissue: Frozen. FFPE: Room temperature. CSF: Frozen. Body Fluid: Frozen | |
| Unacceptable Conditions: | <u>Fingernails, toenails</u> Finger nails, toe nails, or bone. Formalin- fixed paraffin-embedded tissue on slides. <u>All respiratory specimens such as bronchoalveolar lavage</u> (BAL), sputum, etc. | |
| Remarks: | | |
| Stability: | Fresh Tissue: Ambient: 5 days; Refrigerated: 5 days; Frozen: 5 days FFPE: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable CSF and Body Fluid: Ambient: 14 days; Refrigerated: 14 days; Frozen: 14 days | |
| Methodology: | Polymerase Chain Reaction (PCR)/Sequencing | |
| Performed: | Sun, Mon, Wed | |
| Reported: | 3-5 days | |
| Note: | | |
| CPT Codes: | 87999 | |
| New York DOH Approval Status: | Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible. | |
| Interpretive Data: | | |



This assay detects and identifies human fungal pathogens by Sanger sequencing. This assay cannot differentiate invasive fungal infection from environmental fungal DNA. Clinical correlation of sequencing result is recommended.

Reference Interval:



TEST CHANGE

| 1 1 1 1 1 1 1 1 1 1 | Human Immunodeficienc | y Virus 1 (F | HIV-1) by | Quantitative | NAAT, Plas | ma |
|---------------------------------------|-----------------------|--------------|-----------|--------------|------------|----|
|---------------------------------------|-----------------------|--------------|-----------|--------------|------------|----|

| 3000867, HIV QNT | |
|------------------------------------|---|
| Specimen Requirements: | |
| Patient Preparation: | |
| Collect: | Lavender (EDTA), pink (K2EDTA), yellow (ACD), or plasma preparation tube (PPT). |
| Specimen Preparation: | Separate from cells within 24 hours of collection. Transfer 2 mL plasma to an ARUP standard transport tube <u>(ARUP supply</u> <u>#15824)</u> . Available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787. (Minimum volume: 1.3mL) and freeze. (Min: 0.8 mL) |
| Transport Temperature: | Frozen. |
| Unacceptable Conditions: | Serum. CSF (refer to Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, CSF, ARUP test code <u>3017815</u> 3000872). Heparinized specimens. |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 24 hours (Critical: Ship FROZEN); Refrigerated: <u>6 days72 hours</u> ; Frozen: 3 months |
| Methodology: | Quantitative <u>Polymerase Chain Reaction (PCR</u> Transcription- Mediated Amplification (TMA) |
| Performed: | Sun-Sat |
| Reported: | 1-4 days |
| Note: | The limit of quantification for this assay is 1.3 log copies/mL (20 copies/mL). If the assay DETECTED the presence of the virus but was not able to accurately quantify, the test will be reported as "Not Quantified, Detected." |
| CPT Codes: | 87536 |
| New York DOH Approval Status: | This test is New York DOH approved. |
| Interpretive Data: | |
| Normal range for this assay is "No | t Detected." av is 1 3047-7 00 log copies/ml (2030-10 000 000 copies/ml) |



<u>A result</u>

An interpretation of "Not Detected" does not rule out the presence of inhibitors or HIV-1 RNA concentration below the level of detection of the <u>testassay</u>. Care should be taken in the interpretation of any single viral load determination.

This test is intended for use in conjunction with The clinical presentation and other laboratory markers for the clinical management significance of HIV-1 infected patients. The test can be used to assess patient prognosis by measuring the baseline HIV-1 level or to monitor the effects of antiretroviral therapy by measuring changes in HIV-1 RNA levels during the course of antiretroviral treatment. concentration has not been fully established; however, a change of 0.5 log copies/mL-may be significant.

This assay should not be used for blood donor screening, associated reentry protocols, or for screening human <u>cells, tissues, and cellular- or tissue-based products (HCT/P).</u> <u>cell, tissues and cellular tissue-based products (HCT/P).</u>

Note: The limit of quantification for this RNA assay is 1.47 log copies/mL (30 copies/mL). If the assay DETECTED the presence of the virus but was not able to accurately quantify the viral load, the test result will be reported as "<; 30 Detected."

Specimens received with less than minimum volume for testing will automatically be run with a dilution according to the guidelines below:

Specimens with 240-700 uL will be diluted resulting in a modification of the quantitative range of the assay to 1.95-7.48 log copies/mL (90-30,000,000 copies/mL).

This test is intended for use in conjunction with clinical presentation and other laboratory markers as an indicator of disease prognosis. This test is also used as an aid in assessing viral response to antiretroviral treatment as measured by changes in HIV-1 RNA concentration.

Reference Interval:

Not detected.



TEST CHANGE

Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT with Reflex to HIV-1 Drug Resistance by Next Generation Sequencing

3000870, HIV QT GR

Specimen Requirements:

| Patient Preparation: | |
|-------------------------------|---|
| Collect: | Lavender (EDTA), pink (K2EDTA), or plasma preparation tube (PPT). |
| Specimen Preparation: | Separate from cells within 24 hours of collection. Transfer 4 mL plasma to an ARUP standard transport tube (<u>ARUP supply</u> <u>#15824</u>). Available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787. (<u>Minimum volume: 2.5 mL</u>) and freeze. (<u>Min: 2.5 mL</u>) |
| Transport Temperature: | Frozen |
| Unacceptable Conditions: | Serum. Heparinized specimens. |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 24 hours (Critical: Ship FROZEN); Refrigerated: 72 hours; Frozen: 3 months |
| Methodology: | Quantitative <u>Polymerase Chain Reaction</u> (<u>PCR)/SequencingTranscription-Mediated Amplification (TMA)</u> |
| Performed: | Sun-Sat |
| Reported: | 2-14 days |
| Note: | If Human Immunodeficiency Virus 1 by Quantitative NAAT result is greater than or equal to 2.70 log copies/mL, then HIV- Drug Resistance by Next Generation Sequencing will be added. Additional charges apply. |
| CPT Codes: | 87536; if reflexed add 87900; 87901; 87906 |
| New York DOH Approval Status: | This test is New York DOH approved. |
| Interpretive Data: | |
| Refer to report | |
| Reference Interval: | |



| Test Number | Components | Reference Interval |
|----------------|--------------------------|--------------------|
| | HIV-1 Qnt by NAAT Interp | Not Detected |

Not Detected



TEST CHANGE

Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, CSF

| Cerebral spinal fluid. |
|--|
| Transfer 2 mL CSF to an ARUP <u>standard transport tube (ARUP</u> <u>supply #15824)</u> . Available online through eSupply using ARUP <u>Connect(TM) or contact ARUP Client Services at 800-522-2787.</u> (Minimum volumeStandard Transport Tube and freeze. (Min: 0. <u>7</u> 8 mL) |
| Frozen |
| Plasma (refer to Human Immunodeficiency Virus 1 (HIV-1) by Quantitative NAAT, Plasma, ARUP test code 3000867). |
| |
| Ambient: <u>24 hours (Critical: Ship FROZEN);Unacceptable;</u> Refrigerated: 5 days; Frozen: <u>30 days</u> 1 month |
| Quantitative <u>Polymerase Chain Reaction (PCR)</u> Transcription- Mediated Amplification |
| Sun-Sat |
| 1-4 days |
| The limit of quantification for this RNA assay is 1.747 log copies/mL (5030 copies/mL). If the assay DETECTED the presence of the virus but was not able to accurately quantify the viral load, the test result will be reported as "-<30-Detected, Not Quantified." |
| 87536 |
| This test is New York DOH approved. |
| |
| |



Normal range for this assay is "Not Detected".

The quantitative range of this <u>testassay</u> is $1.\frac{70}{47}$ -7.00 log copies/mL (5030-10,000,000 copies/mL).

An interpretation of "Not Detected" does not rule out the presence of inhibitors or HIV-1 RNA concentration below the level of detection of the <u>testassay</u>. Care should be taken in the interpretation of any single viral load determination.

The clinical significance of changes in HIV-1 RNA concentration has not been fully established; however, a change of 0.5 log copies/mL may be significant.

This assay should not be used for blood donor screening, associated <u>reentry protocols</u>, or for <u>screening human cells</u>, <u>tissues</u>, <u>and cellular- or tissue-based products (HCT/P)</u>. <u>re-entry protocols</u>, or for screening Human Cell, <u>Tissues and Cellular Tissue-Based Products (HCT/P)</u>.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Reference Interval:

Not detected



TEST CHANGE

Creatinine With eGFRGlomerular Filtration Rate (Estimated) 3005478, GFR EST Specimen Requirements: Patient Preparation: Collect: Plasma separator tube or serum separator tube. Allow specimen to clot completely at room temperature. Specimen Preparation: Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP standard transport tube. Standard Transport Tube. (Min: 0.2 mL) Transport Temperature: Refrigerated. Unacceptable Conditions: Specimens obtained through catheters used to infuse hyperalimentation fluid. Specimens collected with potassium oxalate/sodium fluoride or sodium citrate. Remarks: Patient age and sex are required for calculation. Stability: After separation from cells: Ambient: 1 week; Refrigerated: 1 week; Frozen: 3 months Methodology: Quantitative Enzymatic Assay Performed: Sun-Sat Within 24 hours Reported: Note: CPT Codes: 82565 New York DOH Approval Status: This test is New York DOH approved. Interpretive Data:



The estimated glomerular filtration rate (eGFR) was calculated using the 2021 CKD-EPI eGFR creatinine equation, which does not include race as a factor. This equation is validated in individuals 18 years of age and older. Accurate estimation of GFR requires stable day-to-day creatinine. Creatinine-based eGFR is less accurate in patients with extremes of muscle mass, restriction of dietary protein, ingestion of creatine, extra-renal metabolism of creatinine, or treatment with medications that affect renal tubular creatinine secretion. The eGFR is normalized to a body surface area of 1.73 square meters.

GFR Categories in Chronic Kidney Disease (CKD)

| GFR Category | GFR (mL/min/1.73 square meters) | Interpretation |
|--------------|---------------------------------------|---|
| G1 | 90 or greater | Normal to high* |
| G2 | 60-89 | Mild decrease* |
| G3a | 45-59 | Mild to moderate decrease |
| G3b | 30-44 | Moderate to severe decrease |
| G4 | 15-29 | Severe decrease |
| G5 | 14 or less | Kidney failure |
| | | *In the absence of evidence of kidney damage, neither GFR category G1 nor G2 fulfill the criteria for CKD (Kidney Int Suppl 2013;3:1-150) |

Reference Interval:

Refer to Report

Calculated GFR - >= 60 mL/min / 1.73 square meters



NEW TEST

Click for Pricing

Cytogenomic SNP Microarray, Family-Specific Variant

3005694, ARRAY FSV

| Specimen Requirements: | |
|--------------------------|--|
| Patient Preparation: | |
| Collect: | Green (sodium heparin). Peripheral blood required. Also acceptable: Lavender (K2EDTA). OR one buccal swab using the Oracollect collection kit ensuring the sponge tip does not come in contact with any surface prior to collection. Donor should not eat, drink, smoke, or chew gum for 30 minutes before collecting oral sample. OR cultured fibroblasts. If direct sample from skin biopsy is sent to ARUP, additional culture charges will apply. If sending skin,please order Cytogenetic Grow and Send (ARUP test code 0040182) in addition to this test and ARUP will culture upon receipt (culturing fees will apply). If you have any questions, contact ARUP's Genetics Processing at 800-522-2787 ext. 3301. If the client is unable to culture, order test Cytogenetics Grow and Send (ARUP test code 0040182) in addition to this test and ARUP will culture upon receipt (culturing fees will apply). If you have any questions, contact ARUP's Genetics Processing at 800-522-2787 ext. 3301. If the client is unable to culture, order test Cytogenetics Grow and Send (ARUP test code 0040182) in addition to this test and ARUP will culture upon receipt (culturing fees will apply). If you have any questions, contact ARUP's Genetics Processing at 800-522- 2787 ext. 3301. |
| Specimen Preparation: | Whole Blood: Transport 5 mL in original collection tube. (Min: 2 mL) Buccal Swab: Transport buccal swab in ORAcollect Collection kit (ARUP supply #49295). Available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787. Cultured fibroblasts: Two T-25 flasks at 80 percent confluency. Fill flasks with culture media. Backup cultures must be maintained at the client's institution until testing is complete. |
| Transport Temperature: | Whole Blood: Room temperature Buccal: Ambient Cultured fibroblasts: Ambient: 48 hours; Refrigerated: 48 hours |
| Unacceptable Conditions: | Frozen specimens. Clotted specimens. |
| Remarks: | Documentation of the familial copy number variant (CNV) is required to perform targeted array analysis. Submit a copy of a relative's laboratory test report documenting the CNV for which testing is requested or include the ARUP accession number of the proband. |
| Stability: | Whole Blood: Ambient 48 hours; Refrigerated: 72 hours; Frozen: Unacceptable Buccal: Ambient 7 days; Refrigerated: |



Unacceptable; Frozen: Unacceptable Cultured fibroblasts: Ambient 48 hours; Refrigerated 48 hours; Frozen: Unacceptable

| Methodology: | Genomic Microarray (Oligo-SNP Array) |
|-------------------------------|--|
| Performed: | Sun-Sat |
| Reported: | 10-14 days |
| Note: | Order this test to identify a known deletion or duplication, identified by microarray, in a family member. |
| CPT Codes: | 81229 |
| New York DOH Approval Status: | Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible. |
| Interpretive Data: | |
| Refer to report. | |
| Reference Interval: | |



TEST CHANGE

| Alzheimer's Disease Markers, CSF 3017653, ADMRKS CSF | | | |
|---|--|--|--|
| Specimen Requirements: | | | |
| Patient Preparation: | | | |
| Collect: | CSF | | |
| Specimen Preparation: | Tube type: Preferred: 2.5 ml low-bind polypropylene false bottom CSF tube (Sarstedt, 63.614.625), available in orderable collection kit, ARUP Supply # 58810. Acceptable: Sarstedt 72.703.600 (1.5 ml) or Sarstedt 72.694.600 (2 ml) low-bind screw cap polypropylene microtube. Unacceptable: Standard CSF polystyrene collection tubes are not acceptable as exposing CSF to polystyrene tubes may decrease Abeta42 concentrations. Collection instructions: 1. Perform lumbar puncture and discard the first 1 to 2 ml of CSF 2. Using the drip method, collect CSF directly into low-bind polypropylene false bottom CSF tube (ARUP Supply #58810) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787. Avoid use of syringes or extension tubing. Fill tube at least 50% full. 3. Freeze and send specimen in original polypropylene collection tube (do not aliquot). | | |
| Transport Temperature: | -20 Degrees C: Critical frozen | | |
| Unacceptable Conditions: | Specimen types other than those listed and hemolyzed CSF. Specimens too viscous to be aspirated by instrument. | | |
| Remarks: | | | |
| Stability: | Frozen: 8 weeks | | |
| Methodology: | Quantitative Electrochemiluminescent Immunoassay (ECLIA) | | |
| Performed: | Mon | | |
| Reported: | 1-7 days | | |
| Note: | | | |
| CPT Codes: | 83520 x3 | | |
| New York DOH Approval Status: | New York DOH Approval Status: This test is New York DOH approved. | | |
| Interpretive Data: | | | |



Interpretive information: The Alzheimer's Disease Markers, CSF panel is intended for use in adult patients aged 55 years and older being evaluated for Alzheimer's disease (AD) and other causes of cognitive impairment. The pTau181/Abeta42 and tTau/Abeta42 ratios provide better concordance with amyloid positron emission tomography (PET) imaging when compared to Abeta42, pTau181, and tTau individually.

Limitations: Failure to adhere to the sample collection instructions provided in the Laboratory Test Directory may result in falsely reduced Abeta42 concentrations and therefore false elevations in the reported ratios. The ratios reported have not been established for predicting development of dementia or other neurologic conditions or for monitoring responses to therapies. Results of this test must always be interpreted in the context other clinical diagnostic evaluations and should not be used alone to establish a diagnosis of AD or other cognitive disorder.

Methodology: Roche Diagnostics Inc. electrochemiluminescence assay was used. Results obtained with different assay methods or kits may be different and cannot be used interchangeably.

| Phospho-Tau (181P) CSF/ß- Amyloid (1-42) CSF ratio | Interpretation |
|---|--|
| <= 0.023 | A negative result, defined as pTau181/Abeta42 ratio value below cutoff, is consistent with a negative amyloid positron emission tomography (PET) scan result. A negative result reduces the likelihood that a patient's cognitive impairment is due to AD. |
| > 0.023 | A positive result, defined as pTau181/Abeta42 ratio value above cutoff, is consistent with a positive amyloid PET scan result. A positive result does not establish a diagnosis of AD or other cognitive disorder. |
| Total Tau CSF/ß- Amyloid (1-42) CSF ratio | Interpretation |
| <= 0.28 | A negative result, |



Reference Interval:

| Test Number | Components | Reference Interval |
|----------------|-------------------------------------|--------------------|
| | Phospho-Tau(181)/Abeta42 Ratio, CSF | <= 0.023 |
| | Total-Tau/Abeta42 Ratio, CSF | <= 0.28 |

HOTLINE NOTE: There is a price change associated with this test. Please contact ARUP Client Services at (800) 522-2787 for additional information.



NEW TEST

Click for Pricing

Human Immunodeficiency Virus 1 and 2 (HIV-1/HIV-2) by Qualitative NAAT

3017779, HIV1,2QUAL

| Specimen Requirements: | | |
|-------------------------------|---|--|
| Patient Preparation: | | |
| Collect: | Lavender (EDTA) (PPT), or serum | , pink (K2EDTA), plasma preparation tube separator tube (SST). |
| Specimen Preparation: | Separate from co plasma to an AR #15824). Availab Connect(TM) or (Minimum volum | ells within 24 hours of collection. Transfer 2 mL UP standard transport tube (ARUP supply ole online through eSupply using ARUP contact ARUP Client Services at 800-522-2787. ne: 1.3mL) |
| Transport Temperature: | Frozen | |
| Unacceptable Conditions: | Heparinized spec | cimens. |
| Remarks: | | |
| Stability: | After separation days; Frozen: 6 v | from cells: Ambient: 24 hrs; Refrigerated: 5 veeks. |
| Methodology: | Qualitative Polyr | nerase Chain Reaction (PCR) |
| Performed: | Sun-Sat | |
| Reported: | 1-4 days | |
| Note: | Test detects and Proviral DNA will | differentiates HIV-1 and HIV-2 virus RNA. not be detected. |
| CPT Codes: | 87535 | |
| New York DOH Approval Status: | This test is New | York DOH approved. |
| Interpretive Data: | | |
| Reference Interval: | | |
| Test Components Number | | Reference Interval |





NEW TEST – Available Now

Click for Pricing

Mismatch Repair Panel by Immunohistochemistry

| 3017828, SO MSI IHC | | | |
|--------------------------|---|--|--|
| Specimen Requirements: | | | |
| Patient Preparation: | | | |
| Collect: | Tumor tissue. | | |
| Specimen Preparation: | Formalin fix (10 percent neutral buffered formalin is preferred) and paraffin embed specimen. If sending precut slides, do not oven bake. Transport tissue block or 10 unstained (3-5 micron thick sections), positively charged slides in a tissue transport kit (ARUP supply #47808) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787. (Min: 5 slides). Protect paraffin block and/or slides from excessive heat. | | |
| Transport Temperature: | Room temperature or refrigerated. Ship in cooled container during summer months. | | |
| Unacceptable Conditions: | Frozen specimens. Specimens fixed or processed in alternative fixatives (alcohol, Prefer) or heavy metal fixatives (B-4 or B-5). Depleted or no tumor in tissue. Specimens submitted with nonrepresentative tissue type. Decalcified specimens. | | |
| Remarks: | Only tissue that is clearly carcinoma (established by histological criteria) should be tested. Include surgical pathology report. Submit electronic request. If you do not have electronic ordering capability, use an ARUP requisition form complete with an ARUP client number. For additional technical details, please contact ARUP Client Services at 800-522-2787. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by one of the following: an order comment indicating that the ARUP pathologist should choose the specimen most appropriate for testing (e.g., "Choose best block"), or individual orders for each sample submitted. A Pathologist Block Selection Fee (ARUP test code 3002076) will be added to orders that utilize the first option. If multiple specimens are sent to ARUP without a request for pathologist block/slide selection or individual orders, they will be held until clarification is provided. | | |
| Stability: | Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable | | |



| Methodology: | Qualitative Immu | unohistochemistry |
|-------------------------------|--|---|
| Performed: | Mon-Fri | |
| Reported: | 1-3 days | |
| Note: | This orderable is MSH2, MSH6, ar This orderable is service only. Ple pathologist inter | offered as a panel only. Individual MLH1, ad PMS2 IHC stains are not offered at this time. performed as a stain and return (technical) ase refer to ARUP test code 0049302 if ARUP pretation is needed. |
| CPT Codes: | 88342/88341x3 | |
| New York DOH Approval Status: | This test is New | York DOH approved. |
| Interpretive Data: | | |
| Reference Interval: | | |
| Test Components Number | | Reference Interval |



NEW TEST

| <u>Click for</u> | Pricing | | |
|-------------------------------|---------------------------|--|--|
| Lacosa | mide, Serum 7 LACOSA-S | | |
| Specim | an Bequirements: | | |
| Specific | | | |
| Patie | nt Preparation: | Timing of specin steady-state cor | nen collection: Predose (trough) draw at icentration. |
| Colle | ct: | Plain red. | |
| Spec | imen Preparation: | Separate serum Transfer 1 mL se 0.5 mL) | from cells within 2 hours of collection. erum to an ARUP standard transport tube. (Min: |
| Trans | sport Temperature: | Refrigerated: Als | o acceptable: Room temperature or frozen. |
| Unac | ceptable Conditions: | otable Conditions: Whole blood. Gel separator tubes, light blue (citrate), o (SPS or ACD solution). | |
| Rema | arks: | | |
| Stabi | lity: | Ambient: 48 hou freeze/thaw cyc | rs; Refrigerated: 1 week; Frozen: 1 month 3 es |
| Method | ology: | Quantitative Enz | yme Immunoassay (EIA) |
| Performed: | | Sun-Sat | |
| Reported: | | 1-2 days | |
| Note: | | | |
| CPT Codes: | | 80235 | |
| New York DOH Approval Status: | | This test is New York DOH approved. | |
| Interpre | tive Data: | | |
| Reference Interval: | | | |
| Test Number | Components | | Reference Interval |



NEW TEST

Click for Pricing

Oxcarbazepine Metabolite, Serum

| 3017889, OXCARBAZ | |
|-------------------------------|---|
| Specimen Requirements: | |
| Patient Preparation: | Timing of specimen collection: Predose (trough) draw at steady state concentration. |
| Collect: | Plain red. |
| Specimen Preparation: | Separate serum from cells within 2 hours of collection. Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.5 mL) |
| Transport Temperature: | Refrigerated. |
| Unacceptable Conditions: | Whole blood. Gel separator tubes, light blue (citrate), or yellow (SPS or ACD solution). |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 48 hours; Refrigerated: 1 week; Frozen: 1 month 3 freeze/thaw cycles |
| Methodology: | Quantitative Enzyme Immunoassay (EIA) |
| Performed: | Sun-Sat |
| Reported: | 1-2 days |
| Note: | |
| CPT Codes: | 80183 |
| New York DOH Approval Status: | This test is New York DOH approved. |

Interpretive Data:

This test measures monohydroxyoxcarbazepine (MHD). Adverse effects may include dizziness, fatigue, nausea, headache, somnolence, ataxia, and tremor.

Reference Interval:

| Test Number | Components | Reference Inte | rval |
|----------------|-------------------|----------------------|--------------|
| | OXCARB Metabolite | | |
| | | Therapeutic Range | Toxic Range |
| | | 10.0 - 35.0 ug/mL | >=40.0 ug/mL |





NEW TEST

Click for Pricing

| 14-3-3 eta Protein by ELISA, Serum | | |
|------------------------------------|--|--|
| 3017890, 14-3-3 ETA | | |
| Specimen Requirements: | | |
| Patient Preparation: | | |
| Collect: | Serum separator tube or red top tube. | |
| Specimen Preparation: | Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP standard transport tube. (Min: 0.25 mL) | |
| Transport Temperature: | Refrigerated. | |
| Unacceptable Conditions: | Nonserum, contaminated, heat-inactivated, severely hemolyzed, severely lipemic, or severely icteric specimens. | |
| Remarks: | | |
| Stability: | After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month (avoid repeated freeze/thaw cycles) | |
| Methodology: | Quantitative Enzyme-Linked Immunosorbent Assay (ELISA) | |
| Performed: | Tue | |
| Reported: | 1-8 days | |
| Note: | | |
| CPT Codes: | 83520 | |
| New York DOH Approval Status: | This test is New York DOH approved. | |

Interpretive Data:

The combination of serum 14-3-3 eta with rheumatoid factor (RF) and anticyclic citrullinated peptide (anti-CCP) may enhance sensitivity and demonstrates high specificity for rheumatoid arthritis (RA) diagnosis. Elevated serum 14-3-3 eta levels may be observed in both early and established RA patients, including those who are seronegative for both RF and anti-CCP antibodies. Elevated serum 14-3-3 eta concentrations are predictive of unfavorable clinical and radiological outcomes at diagnosis and posttreatment initiation. Negative or decreased levels of 14-3-3 eta from baseline correlate with diminished radiological progression and suboptimal treatment response.

Reference Interval:



| Test Number | Components | Reference Interval |
|----------------|---------------------------|--------------------|
| | 14-3-3 eta Protein, Serum | 0.19 ng/mL or less |



NEW TEST

Click for Pricing

Early and Established Rheumatoid Arthritis (RA) Panel

3017891, RAPANEL

| Specimen Requirements: | |
|-------------------------------|--|
| Patient Preparation: | Fasting specimen preferred. |
| Collect: | Serum separator tube (SST) or red top. |
| Specimen Preparation: | Allow serum to clot completely at room temperature before centrifuging. Transfer 2 mL serum to an ARUP standard transport tube. (Min: 1 mL) Serum is the only acceptable specimen type for this assay without a disclaimer. |
| Transport Temperature: | Refrigerated. |
| Unacceptable Conditions: | Nonserum, contaminated, heat-inactivated, hemolyzed, icteric, or severely lipemic specimens. |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 1 month (should not be thawed more than once) |
| Methodology: | Semi-Quantitative Enzyme-Linked Immunosorbent Assay (ELISA)/Quantitative Immunoturbidimetry/Quantitative Enzyme-Linked Immunosorbent Assay (ELISA) |
| Performed: | Sun-Sat |
| Reported: | 1-8 days |
| Note: | |
| CPT Codes: | 83520; 86200; 86431 |
| New York DOH Approval Status: | This test is New York DOH approved. |
| Interpretive Data: | |
| Refer to report. | |
| Reference Interval: | |



| Test Number | Components | Reference Interval |
|----------------|--|--------------------|
| | 14-3-3 eta Protein, Serum | 0.19 ng/mL or less |
| | Cyclic Citrullinated Peptide Ab, IgG/A | 19 Units or less |
| | Rheumatoid Factor | 0-14 IU/mL |



NEW TEST

Click for Pricing

| Gabapentin, Serum or Plasma 3017893, GABAP-SP | | |
|--|---|--|
| Specimen Requirements: | | |
| Patient Preparation: | | |
| Collect: | Plain red. Also ao heparin), lavende | cceptable: Dark green (sodium or lithium er (K2 or K3EDTA) or pink (K2EDTA). |
| Specimen Preparation: | Separate serum collection. Trans standard transpo | or plasma from cells within 2 hours of fer 1 mL serum or plasma to an ARUP ort tube. (Min: 0.2 mL) |
| Transport Temperature: | Refrigerated. | |
| Unacceptable Conditions: | Whole blood. Gel (SPS or ACD solu | separator tubes, light blue (citrate), or yellow ution). |
| Remarks: | | |
| Stability: | After separation week; Frozen: 1 ı | from cells: Ambient: 48 Hours; Refrigerated: 1 month 3 freeze/thaw cycles |
| Methodology: | Quantitative Enz | yme Immunoassay (EIA) |
| Performed: | Sun-Sat | |
| Reported: | 1-2 days | |
| Note: | | |
| CPT Codes: | 80171 | |
| New York DOH Approval Status: | This test is New | York DOH approved. |
| Interpretive Data: | | |
| Reference Interval: | | |
| Test Components Number | | Reference Interval |



NEW TEST

Click for Pricing

| SC5b-9 3017902, SC5B-9 | |
|-------------------------------|---|
| Specimen Requirements: | |
| Patient Preparation: | |
| Collect: | Pink (K2EDTA), Tan (K2EDTA), Royal blue (K2EDTA), or Lavender (EDTA). |
| Specimen Preparation: | Separate plasma within 2 hours (1 hour is preferable) by centrifugation ~2700 rpm (1300 100 g) for 10 minutes. Transfer plasma (minimum 0.5 mL) to an ARUP standard transport tube and freeze immediately. |
| Transport Temperature: | CRITICAL FROZEN. Separate specimens must be submitted when multiple tests are ordered. |
| Unacceptable Conditions: | Nonfrozen specimens. Specimens exposed to repeated freeze/thaw cycles. Grossly hemolyzed, lipemic, and icteric specimens. Serum samples. Heparinized and lithium samples. |
| Remarks: | |
| Stability: | Ambient: Unacceptable; Refrigerated: Unacceptable; Frozen: 30 days |
| Methodology: | Quantitative Enzyme-Linked Immunosorbent Assay (ELISA) |
| Performed: | Sun, Wed |
| Reported: | 2-12 days |
| Note: | |
| CPT Codes: | 86160 |
| New York DOH Approval Status: | This test is New York DOH approved. |
| | |

Interpretive Data:

Elevated soluble C5b-9 (SC5b-9) levels indicate recent or ongoing activation of the complement system, while normal or reduced levels suggest no excessive activation. High SC5b-9 concentrations are associated with transplant-associated thrombotic microangiopathy (TA-TMA), a complication of hematopoietic stem cell transplants. Increased SC5b-9 may also occur in various conditions involving primary or secondary complement activation, such as immune-complex disease, infection, atypical hemolytic uremic syndrome, and C3 glomerulopathies. Due to a low specificity for SC5b-9 testing, results should be interpreted in combination with other clinical and



laboratory evidence of disease activity. Plasma SC5b-9 levels may be used to monitor the efficacy of complement inhibitor drugs, as elevated levels suggest insufficient complement blockage to effectively prevent the formation of the terminal attack complex.

Reference Interval:

| Test Number | Components | Reference Interval |
|----------------|---|---------------------------------|
| | C5b9 Soluble Terminal Complement Complex | Less than or equal to 260 ng/mL |



NEW TEST - Available Now

| Click for Pricing | | |
|------------------------------|--|--|
| CD38 by Immunohistochemistry | | |
| 3018046, CD38-IHC | | |
| Specimen Requirements: | | |
| Patient Preparation: | | |
| Collect: | Tissue or cells. | |
| Specimen Preparation: | Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides in a Tissue Transport Kit (ARUP supply #47808 highly recommended) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787 (Min: 2 slides). If sending precut slides, do not oven bake. | |
| Transport Temperature: | Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. | |
| Unacceptable Conditions: | Specimens submitted with nonrepresentative tissue type. Depleted specimens. | |
| Remarks: | IMMUNOHISTOCHEMISTRY ORDERING AND SUBMISSION DETAILS: Submit electronic request. If you do not have electronic ordering capability, use an ARUP Immunohistochemistry Stain Form (#32978) with an ARUP client number. For additional technical details, contact ARUP Client Services at 800-522-2787. | |
| Stability: | Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable | |
| Methodology: | Qualitative Immunohistochemistry (IHC) | |
| Performed: | Mon-Fri | |
| Reported: | 1-3 days | |
| Note: | This test is performed as a stain and return (technical) service only | |
| CPT Codes: | 88342 | |



New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Reference Interval:

| Test | Components | Reference Interval |
|--------|------------|--------------------|
| Number | | |



NEW TEST - Available Now

| Click for Pricing | | |
|---|--|--|
| p120 by Immunohistochemistry 3018056, P120 IHC | / | |
| Specimen Requirements: | | |
| Patient Preparation: | | |
| Collect: | Tissue or cells. | |
| Specimen Preparation: | Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides in a Tissue Transport Kit (ARUP supply #47808 highly recommended) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787 (Min: 2 slides). If sending precut slides, do not oven bake. | |
| Transport Temperature: | Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. | |
| Unacceptable Conditions: | Specimens submitted with nonrepresentative tissue type. Depleted specimens. | |
| Remarks: | IMMUNOHISTOCHEMISTRY ORDERING AND SUBMISSION DETAILS: Submit electronic request. If you do not have electronic ordering capability, use an ARUP Immunohistochemistry Stain Form (#32978) with an ARUP client number. For additional technical details, contact ARUP Client Services at 800-522-2787. | |
| Stability: | Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable | |
| Methodology: | Qualitative Immunohistochemistry (IHC) | |
| Performed: | Mon-Fri | |
| Reported: | 1-3 days | |
| Note: | This test is performed as a stain and return (technical) service only | |
| CPT Codes: | 88342 | |



New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Reference Interval:

| Test | Components | Reference Interval |
|--------|------------|--------------------|
| Number | | |



NEW TEST - Available Now

Click for Pricing

MyoD1 by Immunohistochemistry

| 3018057, MYOD1 IHC | |
|--------------------------|--|
| Specimen Requirements: | |
| Patient Preparation: | |
| Collect: | Tissue or cells. |
| Specimen Preparation: | Formalin fix (10 percent neutral buffered formalin) and paraffin embed specimen (cells must be prepared into a cellblock). Protect paraffin block and/or slides from excessive heat. Transport tissue block or 5 unstained (3- to 5-micron thick sections), positively charged slides in a Tissue Transport Kit (ARUP supply #47808 highly recommended) available online through eSupply using ARUP Connect(TM) or contact ARUP Client Services at 800-522-2787 (Min: 2 slides). If sending precut slides, do not oven bake. |
| Transport Temperature: | Room temperature. Also acceptable: Refrigerated. Ship in cooled container during summer months. |
| Unacceptable Conditions: | Specimens submitted with nonrepresentative tissue type. Depleted specimens. |
| Remarks: | IMMUNOHISTOCHEMISTRY ORDERING AND SUBMISSION DETAILS: Submit electronic request. If you do not have electronic ordering capability, use an ARUP Immunohistochemistry Stain Form (#32978) with an ARUP client number. For additional technical details, contact ARUP Client Services at 800-522-2787. |
| Stability: | Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable |
| Methodology: | Qualitative Immunohistochemistry (IHC) |
| Performed: | Mon-Fri |
| Reported: | 1-3 days |
| Note: | This test is performed as a stain and return (technical) service only |
| CPT Codes: | 88342 |



New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:

Reference Interval:

| Test | Components | Reference Interval |
|--------|------------|--------------------|
| Number | | |



NEW TEST

Click for Pricing

HLA-A29 Genotyping, Birdshot Chorioretinopathy

3018058, HLA A29

| Specimen Requirements: | |
|-------------------------------|--|
| Patient Preparation: | |
| Collect: | Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B). |
| Specimen Preparation: | Transport 5 mL whole blood. (Min: 3 mL). |
| Transport Temperature: | Refrigerated |
| Unacceptable Conditions: | Specimens collected in green (sodium or lithium heparin). |
| Remarks: | |
| Stability: | Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable |
| Methodology: | Polymerase Chain Reaction (PCR)/Sequence-Specific Oligonucleotide Probe Hybridization |
| Performed: | Mon-Fri |
| Reported: | 5-7 days |
| Note: | |
| CPT Codes: | 81381 |
| New York DOH Approval Status: | This test is New York DOH approved. |

Interpretive Data:

Background Information for HLA-A29 Genotyping for Birdshot Chorioretinopathy:

Characteristics: Birdshot chorioretinopathy (BSCR) is a progressive, bilateral, chronic autoimmune inflammatory disease of the eye. It is characterized by posterior uveitis with yellow-white choroid lesions in the fundus that resemble a shotgun splatter. Patients with BSCR may experience decreased vision, floaters, nyctalopia, dyschromatopsia, glare, and photopsia.

Prevalence: BSCR comprises up to 1.5%, of uveitis cases. Its prevalence ranges from 0.1 to 0.6 cases per 100,000 individuals across Europe and the U.S. Particularly prevalent in Caucasians, it is frequently diagnosed in individuals of Northern European ancestry, predominantly affecting middle-aged individuals, (mean onset age of 53 years), with a higher incidence among females.

Inheritance: Multifactorial.



Cause: The disease-causing factors are unknown. HLA-A29 is strongly associated with BSCR, with approximately 80-98% of patients testing positive, compared to about 7% positivity in healthy individuals across different ethnicities. This suggests a negative predictive value of HLA-A29 typing as high as 99%. HLA-A29 is associated with a 50-224 times greater relative risk of developing the disease.

Clinical Sensitivity: Approximately 80-98%, depending on ethnicity.

Methodology: Polymerase Chain Reaction/Sequence-Specific Oligonucleotide Probe Hybridization.

Analytical Sensitivity and Specificity: >99 percent.

Limitations: Other genetic and nongenetic factors that influence BSCR are not evaluated. Other rare, or novel alleles may occur which may lead to false-positive or false-negative results. In cases where an HLA allele cannot be resolved unambiguously, the allele assignment will be reported as the most common, based on allele frequencies from the Common, Intermediate and Well-Documented Alleles Catalogue version 3.0.0 (Hurley CK, et al, 2020).

Alleles tested: HLA-A*29 alleles.

Disclaimer Information:

This test was developed and its performance characteristics determined by the Histocompatibility & Immunogenetics Laboratory at the University of Utah Health under the accreditation guidelines from the American Society for Histocompatibility and Immunogenetics (ASHI).

Performed at: Histocompatibility and Immunogenetics Laboratory, University of Utah Health, 417 Wakara Way, Suite 3220, Salt Lake City, UT 84108.

Counseling and informed consent are recommended for genetic testing. Consent forms are available online.

Reference Interval:

By Report



NEW TEST - Available Now

Click for Pricing

Vasoactive Intestinal Polypeptide (VIP), Plasma

| 3018202, VIP PLA | |
|-------------------------------|--|
| Specimen Requirements: | |
| Patient Preparation: | |
| Collect: | Chilled lavender or pink (K2EDTA or K3EDTA). |
| Specimen Preparation: | Collect in a prechilled tube. Mix well, then place on ice until centrifugation. Transfer 2 mL of plasma to an ARUP standard transport tube (Min: 0.5 mL). Freeze at -20. |
| Transport Temperature: | Frozen. Separate specimens must be submitted when multiple tests are ordered. |
| Unacceptable Conditions: | Grossly hemolyzed, lipemic, icteric, or clotted specimens. |
| Remarks: | |
| Stability: | After separation from cells: Room Temperature: 4 hours; Refrigerated: 24 hours; Frozen: 3 months. |
| Methodology: | Quantitative Enzyme-Linked Immunosorbent Assay (ELISA) |
| Performed: | Mon, Thu |
| Reported: | 3-7 days |
| Note: | |
| CPT Codes: | 84586 |
| New York DOH Approval Status: | Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible. |
| Interpretive Data: | |

Reference Interval:

| Test Number | Test Name | Reference Interval |
|-------------|---|-----------------------|
| 3018312 | Vasoactive Intestinal Polypeptide (VIP) | 0-89.1 pg/mL |





NEW TEST

Click for Pricing

| Cystatin and Creatinine With eGFR 3018316, GFR CYS | | |
|---|---|--|
| Specimen Requirements: | | |
| Patient Preparation: | | |
| Collect: | Serum separator tube, plasma separator tube, K2EDTA, K3EDTA, or lithium heparin | |
| Specimen Preparation: | Allow serum tube to clot completely at room temperature. Separate serum or plasma from cells within 2 hours of collection. Transfer 1 mL plasma or serum or plasma to an ARUP standard transport tube. (Min: 0.2 mL) | |
| Transport Temperature: | Refrigerated. | |
| Unacceptable Conditions: | Blood collected in capillary blood collection tubes is unsuitable for use in this assay. | |
| Remarks: | Patient age and sex are required for calculation. | |
| Stability: | After separation from cells: Ambient: 7 days; Refrigerated: 7 days; Frozen: 3 months | |
| Methodology: | Quantitative Enzymatic Assay | |
| Performed: | Sun-Sat | |
| Reported: | Within 24 hours | |
| Note: | | |
| CPT Codes: | 82610; 82565 | |
| New York DOH Approval Status: | This test is New York DOH approved. | |
| Interpretive Data: | | |



The estimated glomerular filtration rate (eGFR) was calculated using the 2021 CKD-EPI eGFR creatinine-cystatin equation. This equation is validated in individuals 18 years of age and older. Accurate estimation of GFR requires stable day-to-day filtration markers (creatinine and cystatin C). Filtration markers are influenced by non-GFR determinants, including generation from cells and diet, tubular secretion and reabsorption, and extra-renal elimination. These determinants may affect eGFR accuracy. The eGFR is normalized to a body surface area of 1.73 square meters.

| GFR Category | GFR (mL/min/1.73 square meters) | Interpretation |
|--------------|---------------------------------------|---|
| G1 | 90 or greater | Normal to high* |
| G2 | 60-89 | Mild decrease* |
| G3a | 45-59 | Mild to moderate decrease |
| G3b | 30-44 | Moderate to severe decrease |
| G4 | 15-29 | Severe decrease |
| G5 | 14 or less | Kidney failure |
| | | *In the absence of evidence of kidney damage, neither GFR category G1 nor G2 fulfill the criteria for CKD (Kidney Int Suppl 2013;3:1-150) |

Reference Interval:

Refer to Report

Calculated GFR - >= 60 mL/min / 1.73 square meters



NEW TEST – Available Now

Click for Pricing

Allergen, Food, Walnut Component rJug r 1, IgE

3018558, JUG R 1

| Specimen Requirements: | |
|-------------------------------|--|
| Patient Preparation: | Multiple patient encounters should be avoided. |
| Collect: | Serum separator tube. |
| Specimen Preparation: | Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP standard transport tube. (Min: 0.25 mL). For multiple allergen orders refer to "Allergen Specimen Collection Instructions" at www.aruplab.com/testing/resources/specimen. |
| Transport Temperature: | Refrigerated. |
| Unacceptable Conditions: | Postmortem samples |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month |
| Methodology: | Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay |
| Performed: | Sun-Sat |
| Reported: | 1-3 days |
| Note: | |
| CPT Codes: | 86008 |
| New York DOH Approval Status: | This test is New York DOH approved. |
| Interpretive Data: | |



Allergen results of 0.10-0.34 kU/L are intended for specialist use as the clinical relevance is undetermined. Even though increasing ranges are reflective of increasing concentrations of allergen-specific IgE, these concentrations may not correlate with the degree of clinical response or skin testing results when challenged with a specific allergen. The correlation of allergy laboratory results with clinical history and in vivo reactivity to specific allergens is essential. A negative test may not rule out clinical allergy or even anaphylaxis.

| Reporting Range (reported in kU/L) | Probability of IgE Mediated Clinical Reaction | Class Scoring | |
|---------------------------------------|---|---------------|--|
| Less than 0.10 | No significant level detected | 0 | |
| 0.10-0.34 | Clinical relevance undetermined | 0/1 | |
| 0.35-0.70 | Low | 1 | |
| 0.71-3.50 | Moderate | 2 | |
| 3.51-17.50 | High | 3 | |
| 17.51-50.00 | Very high | 4 | |
| 20.01-100.00 | Very high | 5 | |
| Greater than 100.00 | Very high | 6 | |

Reference Interval:

| Test Number | Components | Reference Interval |
|----------------|---------------------------|---------------------------------|
| | Allergen, Walnut rJug r 1 | Less than or equal to 0.09 kU/L |



NEW TEST – Available Now

Click for Pricing

Allergen, Food, Walnut (Juglans spp.) With Reflex to Components, IgE

3018559, WALNUT R

| Specimen Requirements: | |
|-------------------------------|--|
| Patient Preparation: | Multiple patient encounters should be avoided. |
| Collect: | Serum separator tube. |
| Specimen Preparation: | Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP standard transport tube. (Min: 0.35 mL). For multiple allergen orders refer to "Allergen Specimen Collection Instructions" at www.aruplab.com/testing/resources/specimen. |
| Transport Temperature: | Refrigerated |
| Unacceptable Conditions: | Postmortem samples |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month |
| Methodology: | Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay |
| Performed: | Sun-Sat |
| Reported: | 1-3 days |
| Note: | This assay will initially test walnut whole allergen. If the walnut whole allergen result is greater than or equal to 0.1 kU/L, walnut components rJug r 1 and rJug r 3 will be ordered. Additional charges apply. |
| CPT Codes: | 86003; if reflexed order 86008x2 |
| New York DOH Approval Status: | This test is New York DOH approved. |
| Interpretive Data: | |



Allergen results of 0.10-0.34 kU/L are intended for specialist use as the clinical relevance is undetermined. Even though increasing ranges are reflective of increasing concentrations of allergen-specific IgE, these concentrations may not correlate with the degree of clinical response or skin testing results when challenged with a specific allergen. The correlation of allergy laboratory results with clinical history and in vivo reactivity to specific allergens is essential. A negative test may not rule out clinical allergy or even anaphylaxis.

| Reporting Range (reported in Ku/L) | Probability of IgE Mediated Clinical Reaction | Class Scoring | |
|---------------------------------------|---|---------------|--|
| Less than 0.10 | No significant level detected | 0 | |
| 0.10-0.34 | Clinical relevance undetermined | 0/1 | |
| 0.35-0.70 | Low | 1 | |
| 0.71-3.50 | Moderate | 2 | |
| 3.51-17.50 | High | 3 | |
| 17.51-50.00 | Very high | 4 | |
| 50.01-100.00 | Very high | 5 | |
| Greater than 100.00 | Very high | 6 | |

Reference Interval:

| Test Number | Components | Reference Interval |
|----------------|--|---------------------------------|
| | Allergen, Food, Walnut (Juglans spp) IgE | Less than or equal to 0.34 kU/L |



NEW TEST – Available Now

Click for Pricing

Allergen, Food, Cashew Component rAna o 3, IgE

3018561, ANA O 3

| Specimen Requirements: | |
|-------------------------------|--|
| Patient Preparation: | Multiple patient encounters should be avoided. |
| Collect: | Serum separator tube. |
| Specimen Preparation: | Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP standard transport tube. (Min: 0.25 mL). For multiple allergen orders refer to "Allergen Specimen Collection Instructions" at www.aruplab.com/testing/resources/specimen. |
| Transport Temperature: | Refrigerated. |
| Unacceptable Conditions: | Postmortem samples |
| Remarks: | |
| Stability: | After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month |
| Methodology: | Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay |
| Performed: | Sun-Sat |
| Reported: | 1-3 days |
| Note: | |
| CPT Codes: | 86008 |
| New York DOH Approval Status: | This test is New York DOH approved. |
| Interpretive Data: | |



Allergen results of 0.10-0.34 kU/L are intended for specialist use as the clinical relevance is undetermined. Even though increasing ranges are reflective of increasing concentrations of allergen-specific IgE, these concentrations may not correlate with the degree of clinical response or skin testing results when challenged with a specific allergen. The correlation of allergy laboratory results with clinical history and in vivo reactivity to specific allergens is essential. A negative test may not rule out clinical allergy or even anaphylaxis.

| Reporting Range (reported in kU/L) | Probability of IgE Mediated Clinical Reaction | Class Scoring | |
|---------------------------------------|---|---------------|--|
| Less than 0.10 | No significant level detected | 0 | |
| 0.10-0.34 | Clinical relevance undetermined | 0/1 | |
| 0.35-0.70 | Low | 1 | |
| 0.71-3.50 | Moderate | 2 | |
| 3.51-17.50 | High | 3 | |
| 17.51-50.00 | Very high | 4 | |
| 20.01-100.00 | Very high | 5 | |
| Greater than 100.00 | Very high | 6 | |

Reference Interval:

| Test Number | Components | Reference Interval |
|----------------|--------------------------------------|---------------------------------|
| | Allergen, Cashew Component, rAna o 3 | Less than or equal to 0.09 kU/L |



NEW TEST – Available Now

Click for Pricing

Allergen, Food, Cashew With Reflex to Components, IgE

3018562, CASHEW R

| Interpretive Data: | |
|-------------------------------|--|
| New York DOH Approval Status: | This test is New York DOH approved. |
| CPT Codes: | 86003; if reflexed add 86008 |
| Note: | This assay will initially test cashew whole allergen. If the cashew whole allergen result is greater than or equal to 0.1 kU/L, the cashew component rAna o 3 will be ordered. Additional charges apply. |
| Reported: | 1-3 days |
| Performed: | Sun-Sat |
| Methodology: | Quantitative ImmunoCAP Fluorescent Enzyme Immunoassay |
| Remarks: Stability: | After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 1 month |
| Unacceptable Conditions. | Postmontern samples |
| Transport Temperature: | Refrigerated. |
| Specimen Preparation: | Separate serum from cells ASAP or within 2 hours of collection. Transfer 0.5 mL serum to an ARUP standard transport tube. (Min: 0.35 mL). For multiple allergen orders refer to "Allergen Specimen Collection Instructions" at www.aruplab.com/testing/resources/specimen. |
| Collect: | Serum separator tube. |
| Patient Preparation: | Multiple patient encounters should be avoided. |
| Specimen Requirements: | |



Allergen results of 0.10-0.34 kU/L are intended for specialist use as the clinical relevance is undetermined. Even though increasing ranges are reflective of increasing concentrations of allergen-specific IgE, these concentrations may not correlate with the degree of clinical response or skin testing results when challenged with a specific allergen. The correlation of allergy laboratory results with clinical history and in vivo reactivity to specific allergens is essential. A negative test may not rule out clinical allergy or even anaphylaxis.

| Reporting Range (reported in kU/L) | Probability of IgE Mediated Clinical Reaction | Class Scoring | |
|---------------------------------------|---|---------------|--|
| Less than 0.10 | No significant level detected | 0 | |
| 0.10-0.34 | Clinical relevance undetermined | 0/1 | |
| 0.35-0.70 | Low | 1 | |
| 0.71-3.50 | Moderate | 2 | |
| 3.51-17.50 | High | 3 | |
| 17.51-50.00 | Very High | 4 | |
| 50.01-100.00 | Very High | 5 | |
| Greater than 100.00 | Very High | 6 | |

Reference Interval:

| Test Number | Components | Reference Interval |
|----------------|----------------------------|---------------------------------|
| | Allergen, Food, Cashew IgE | Less than or equal to 0.34 kU/L |



A nonprofit enterprise of the University of Utah and its Department of Pathology

Inactivations

The following will be discontinued from ARUP's test menu on October 21, 2024 Replacement test options are indicated when applicable.

| Test Number | Test Name | Refer to Replacement Test |
|-------------|---|--|
| 0020407 | Lactose Tolerance(Inactive as of 10/21/24) | |
| 0082024 | Fetal Fibronectin(Inactive as of 10/21/24) | |
| 0090001 | Acetaminophen(Inactive as of 10/21/24) | |
| 0090057 | Gabapentin (Change effective as of 10/21/2024: Refer to 3017893 in the October Hotline) | Gabapentin, Level (3017893) |
| 0090090 | Phenytoin(Change effective as of 10/21/24: Refer to 0090141 in the October Hotline) | Phenytoin, Free And Total (0090141) |
| 0090251 | Salicylate Assay(Inactive as of 10/21/24) | |
| 0090260 | Carbamazepine, Total(Change effective as of 10/21/24: Refer to 2011763 in the October Hotline) | Carbamazepine, Free and Total, Ser/Pla (2011763) |
| 0090290 | Valproic Acid(Change effective as of 10/21/24: Refer to 0099310 in the October Hotline) | Valproic Acid, Free (0099310) |
| 0095229 | Cystatin C, Serum with Reflex to Estimated Glomerular Filtration Rate (eGFR) (Change effective as of 10/21/24: Refer to 3018316 in the October Hotline.) | Cystatin and Creatinine With eGFR (3018316) |
| 0098834 | Oxcarbazepine or Eslicarbazepine Metabolite (MHD) (Change effective as of 10/21/2024: Refer to 3017889 in the October Hotline) | Oxcarbazepine or Eslicarbazepine Metabolite (MHD) (3017889) |



| Test Number | Test Name | Refer to Replacement Test |
|-------------|--|--|
| 2000133 | Cytology, SurePath Liquid-Based Pap Test and Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, SurePath. (for routine co-testing in women over 30) (Change effective as of 10/21/2024: Refer to 2000136) | Cytology, ThinPrep Pap Test and Human Papillomavirus (HPV) High Risk Screen by Transcription-Mediated Amplification (TMA), With Reflex to Genotypes 16 and 18/45 (2000136) |
| 2000134 | Cytology, SurePath Liquid-Based Pap Test (Change effective as of 10/21/2024: Refer to 2000137) | Cytology, ThinPrep Pap Test (2000137) |
| 2000135 | Cytology, SurePath Liquid-Based Pap Test with Reflex to Human Papillomavirus (HPV), High Risk with 16 and 18 Genotype by PCR, SurePath (Change effective as of 10/21/2024: Refer to 2000138) | Cytology, ThinPrep Pap Test With Reflex to Human Papillomavirus (HPV), High Risk Screen by Transcription-Mediated Amplification (TMA), With Reflex to Genotypes 16 and 18/45 (2000138) |
| 2003182 | Lacosamide, Serum or Plasma (Change effective as of 10/21/2024: Refer to 3017887 in the October Hotline) | Lacosamide, Serum (3017887) |
| 3003760 | Human Immunodeficiency Virus 1 (HIV-1) by Qualitative NAAT (Change effective as of 10/21/24; Refer to 3017779 in the October Hotline) | Human Immunodeficiency Virus 1 & 2 (HIV- 1/HIV-2) by Qualitative NAAT (3017779) |